Silkworm model for *Bacillus anthracis* infection and virulence determination

Atmika Paudel, Yoshikazu Furuta, and Hideaki Higashi

Division of Infection and Immunity, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Hokkaido, Japan

**ABSTRACT**

*Bacillus anthracis* is an obligate pathogen and a causative agent of anthrax. Its major virulence factors are plasmid-coded; however, recent studies have revealed chromosome-encoded virulence factors, indicating that the current understanding of its virulence mechanism is elusive and needs further investigation. In this study, we established a silkworm (*Bombyx mori*) infection model of *B. anthracis*. We showed that silkworms were killed by *B. anthracis* Sterne and cured of the infection when administered with antibiotics. We quantitatively determined the lethal dose of the bacteria that kills 50% larvae and effective doses of antibiotics that cure 50% infected larvae. Furthermore, we demonstrated that *B. anthracis* mutants with disruption in virulence genes such as *pagA*, *lef*, and *atxA* had attenuated silkworm-killing ability and reduced colonization in silkworm hemolymph. The silkworm infection model established in this study can be utilized in large-scale infection experiments to identify novel virulence determinants and develop novel therapeutic options against *B. anthracis* infections.

**Introduction**

*Bacillus anthracis* is a spore-forming Gram-positive bacterium that infects both animals and humans. Most animals ingest *B. anthracis* spores while grazing and develop an infection, and humans occasionally acquire infection from the infected animals or animal products. The spore-forming ability allows the bacteria to exist for decades in a dormant state and resist harsh environments [1]. Despite immunization efforts, *B. anthracis* is still a potential threat due to sporadic anthrax outbreaks [2–9] and its use in bioterrorism [10]. Consequently, the world health organization and centers for disease control and prevention have placed *B. anthracis* as one of the top bioterrorism agents.

The pathogenicity of *B. anthracis* has been attributed mainly to toxins and capsule encoded in the plasmids pXO1 and pXO2, respectively [11,12]. Emerging evidence has uncovered the involvement of chromosomal genes in virulence [13–18], implying that other virulence factors of *B. anthracis* are yet to be identified. As pathogenesis is an outcome of host-pathogen interaction, a suitable animal host is desired to understand virulence mechanisms and design novel therapeutic approaches. A model that can be used in large numbers and have fewer ethical concerns would be of particular importance during the initial phases of research. Due to economic, technical, and ethical concerns associated with the use of vertebrate animals, scientists are turning toward invertebrate animal models such as *Caenorhabditis elegans* [19–21], *Drosophila melanogaster* [22–24], *Galleria mellonella* [25–27] and *Bombyx mori* (silkworm) [28–30] for large scale screenings. Accurate dose administration in *C. elegans* and *D. melanogaster* is difficult due to their small size. Due to the faster locomotion and smaller size of *G. mellonella* larvae (~2 cm), injection experiments are relatively difficult, and there is an increased risk of needle injury to the personnel, necessitating the use of additional restraint and personnel protective equipment [31,32]. Moreover, the ability of adult wax moths to fly increases the chance of their escape from the laboratory. Silkworm larvae have been used as a desirable animal model with many physical and biological advantages [33]. They are small enough for easy handling yet large enough (~5 cm) to perform experiments involving organ isolations and desired quantity injections. Besides, due to their slow locomotion, harmless nature, and the inability of adult silk moths to fly, they have less biohazard potential. Conserved basic biological features with mammals make silkworms appropriate as animal models of human diseases [34–36]. Using silkworms as an infection model, novel antimicrobial agents and novel genes with roles in bacterial virulence have been identified [28,29,37–40].

In this study, we established a silkworm model of *B. anthracis* infection. We demonstrated that *B. anthracis* kills silkworms, and the infection can be treated by clinically used antibiotics. Using a fluorescent protein-expressing strain, we revealed how *B. anthracis* establishes infection...
inside the host. We further showed that mutants with disruption in the genes encoding known virulence factors had decreased virulence in silkworms.

Materials and methods

Bacterial strains and culture condition

The bacterial strains used in this study are shown in Table 1. *B. anthracis* 34F2 with pRP1099, a plasmid possessing the gene for AmCyan1 protein, was constructed by conjugation [41]. Strains were grown in Brain-Heart Infusion (BHI) medium (Difco, USA) for routine culture at 37°C. Kanamycin (20 µg/ml) was supplemented for BYF10124. For liquid cultures, strains were grown at 37°C with shaking at 155 rpm.

Silkworm rearing

Silkworm eggs were purchased from Ehime-Sanshu Co., Ltd. (Ehime, Japan), disinfected, and reared at 27°C. The worms were fed with antibiotic-containing artificial diet Silkmate 2S (Nihon Nosan Corp., Japan) until the fifth instar stage as previously described [38]. After the larvae turn to the fifth instar, they were fed an antibiotic-free artificial diet (Sysmex, Japan) and used for infection experiments the following day.

Silkworm infection experiments

For infection experiments, fifth-instar day-2 silkworm larvae were used. Bacterial strains were revived from glycerol stock by streaking them on BHI agar plates and incubating overnight at 37°C. The overnight grown single colony was inoculated and cultured overnight in 5 ml BHI medium with shaking at 155 rpm. The culture was 100-fold diluted in BHI medium and grown till the OD_{600} reached 0.5. The cells were diluted with physiological saline solution (0.9% NaCl), where applicable, and 50 µl of bacterial suspension was injected into the hemolymph of each larva using a 1-ml syringe equipped with a 27-gauge needle (Terumo Medical Corporation, Japan). The infected worms were incubated at 27°C, and their survival was recorded. Although silkworms survive at 37°C, they are more sensitive toward infection at this temperature [42,43]. Therefore, for highly pathogenic microorganisms, we routinely incubate silkworm larvae at 27°C post-infection. Silkworms were considered dead if they did not move when poked with forceps.

Antimicrobial susceptibility test

Antibiotics were obtained from either Fujifilm Wako, Japan, or Sigma Aldrich, Japan. Antimicrobial susceptibility test was performed by broth micro-dilution assay according to the Clinical and Laboratory Standards Institute protocol (CLSI) as explained previously [38]. The plate was incubated at 37°C for 20 h, and the minimum inhibitory concentration (MIC) of each antibiotic was determined as the minimum concentration that inhibited the growth of bacteria.

Treatment of infection by antibiotics in silkworms

To evaluate the therapeutic activities of clinically used antibiotics in the infected silkworms, exponentially growing bacteria (~5 x 10^2 CFU) was injected into the hemolymph of each larva. Different concentrations of antibiotics were prepared in saline and injected into the larval hemolymph within 30 min of infection. For survival assay, 1 mg/kg of doxycycline and ampicillin each were injected into the larvae. To determine effective doses that cure 50% larvae (ED_{50}), various concentrations of doxycycline and ampicillin were prepared in saline and injected into the hemolymph of infected larvae (n = 3 for each dose). The survival of larvae was recorded, and ED_{50} was calculated from the survival at 16 h post-infection by logistic regression analysis using the logit link function. To determine the microbial burden, larvae infected with *B. anthracis* (6 x 10^2 CFU/larva) were injected with doxycycline and ampicillin (1 mg/kg; n = 10) within 30 min of infection, hemolymph was collected 6 h and 9 h post-injection, diluted with saline and spread on Luria-Bertani agar plates followed by overnight incubation at 37°C. The appearing colonies were counted the next day.

Fluorescence imaging

*B. anthracis* BYF10124 was injected into silkworm hemolymph. The silkworms were kept at 27°C. After 3 h and 6 h post-infection, hemolymph from the infected silkworm was collected, placed on a glass slide, and covered by a coverslip. Fluorescence images of the samples were collected using an inverted Zeiss LSM 780 confocal microscope equipped with an EM-CDD camera (Zeiss Research Microscopy Solutions, Germany) under a 40 x objective lens. To determine

Table 1. Bacterial strains used in this study.

| Strain   | Description                                      | Reference |
|----------|--------------------------------------------------|-----------|
| 3F2      | *Bacillus anthracis* Sterne, vaccine strain (pXO1*, pXO2*) | [66]      |
| BYF10008 | Strain derived from 3F2, ΔpapA                   | [49]      |
| BYF10054 | Strain derived from 3F2, ΔbatA                   | [49]      |
| BYF10009 | Strain derived from 3F2, Δlef                    | [49]      |
| BYF10124 | 3F2 harboring pRP1099, expressing fluorescent protein AmCyan1 | This study |
the effect of the antibiotic, 1 mg/kg ampicillin was injected into the infected larvae, and hemolymph was observed under the microscope.

**Assessment of virulence in silkworms**

Virulence of the bacterial strains in silkworms was tested by injecting the exponentially growing *B. anthracis* 34F2 and mutants with disruption in virulence genes (~5 x 10^2 CFU) into the hemolymph of each larva. For survival, larvae were observed at different time intervals post-infection. To determine microbial burden, hemolymph of the infected larva was collected at 3 h and 6 h post-infection, diluted in saline, and colony-forming units were determined. For LD50 determination, exponentially growing cells were serially diluted and injected into the larval hemolymph (n = 3/group). The survival of larvae was recorded, and LD50 was calculated from the survival at 16 h post-infection by logistic regression analysis using the logit link function.

**Results**

**Silkworms are killed by *Bacillus anthracis* infection**

To establish a *B. anthracis* silkworm infection model, we injected different cell numbers of *B. anthracis* Sterne strain 34F2 into silkworm larvae hemolymph and observed the survival. We found that *B. anthracis* killed the silkworms in a dose-dependent manner (Figure 1(a)). We determined the lethal dose that killed 50% of the worms (LD50) 16 h post-infection to be 8.3 x 10^2 colony forming units (CFU) per larva (Figure 1(b)). At 19 h post-infection, when all the silkworms infected with 8.1 x 10^2 CFU of *B. anthracis* died (Figure 1(c)), saline-injected silkworms were still surviving (Figure 1(d)), indicating that the fatality is brought about by *B. anthracis* infection. The death of larvae was accompanied by a change of skin color to pale followed by black due to melanization as a secondary indicator of death after the lack of motion upon prodding. To further confirm that the observed killing of silkworms

![Figure 1. *Bacillus anthracis* kills silkworms. a. Dose-dependent killing of silkworms by *B. anthracis*. Data is representative of three independent experiments. b. Survival of silkworms 16 h post-infection. Data are presented as a combined result of three independent experiments. LD50 is calculated by logistic regression analysis using the logit link function. c. Dead silkworms infected with *B. anthracis* (8.1 x 10^2 CFU/larva) 19 h post-infection. The dead silkworms turn black due to melanization. d. Alive silkworms injected with saline 19 h post-injection.](image-url)
was due to *B. anthracis* infection, we heat-killed the bacteria by autoclaving and injected into the silkworms. We found that injection of heat-killed bacteria equivalent to $1.5 \times 10^6$ CFU did not kill the worms while live $2.6 \times 10^3$ CFU killed the worms within 16 h post-infection (Figure 2(a)). We further constructed fluorescent protein AmCyan1-expressing *B. anthracis*, whose silkworm killing ability was similar to that of the wild-type (Figure 2(b)). We confirmed the fluorescence-protein expression by observing the cells under a fluorescence microscope (Figure 2(c)). We then infected the silkworm with the bacteria, recovered hemolymph 3 h and 6 h post-infection, and confirmed the fluorescence expression of bacteria in the hemolymph. While most of the bacteria were engulfed by hemocytes 3 h post-infection (Figure 2(d)), increased bacterial growth outside the hemocytes was observed 6 h post-infection (Figure 2(e)), indicating the progression of bacterial proliferation within the host and establishment of infection by the bacteria.

![Figure 2](image-url)

**Figure 2.** Live bacteria is required for silkworm killing. a. Survival of silkworms after injection of heat-killed *B. anthracis*. Live *B. anthracis* ($2.6 \times 10^3$ CFU/larva) and heat-killed *B. anthracis* ($1.5 \times 10^6$ CFU/larva) were injected to silkworms ($n = 8$), and survival was observed. Representative data of two independent experiments are shown. b. Survival of silkworms after infection with wild-type and BYF10124. Wild-type *B. anthracis* ($5 \times 10^2$ CFU/larva) and BYF10124 ($8.5 \times 10^2$ CFU/larva) were injected to silkworms ($n = 7$), and survival was observed. Representative data of two independent experiments are shown. c. *In vitro* grown BYF10124 under the microscope. d, e. BYF10124 in silkworm hemolymph 3 h (d) and 6 h (e) post-infection under the microscope. White arrow-heads show representative hemocytes of silkworm hemolymph. Scale bars, 20 µm.
**Infection is cured by antibiotics treatment**

After confirming that *B. anthracis* establishes infection in silkworms and kills them, we evaluated the therapeutic effectiveness of clinically used antibiotics against *B. anthracis* infection. At first, we determined the *in vitro* antimicrobial susceptibility of *B. anthracis* toward a range of antibiotics. Consistent with reported studies [44–46], we found that it was susceptible to most of the antibiotics tested and resistant to bacitracin and fosfomycin (Table 2). Next, we selected two antibiotics that are commonly used for the treatment of anthrax, doxycycline and ampicillin, and injected them into the hemolymph of silkworms infected with *B. anthracis*. We found that both antibiotics cured silkworms and prevented their death (Figure 3(a)). We further determined the dose-response of doxycycline and ampicillin and calculated the effective doses that cure 50% of the worms (ED$_{50}$) 16 h post-infection to be 0.05 mg/kg and 0.02 mg/kg, respectively (Figure 3(b-c)). We next, determined the bacterial burden in the silkworm hemolymph at different intervals of time post-infection and found that the number of viable cells decreased with time in the antibiotic-treated groups (Figure 3(d)). In addition, we checked the fluorescence expression after administering ampicillin to the BYF10124 infected larvae. We found that after 3 h post-infection, most of the hemocytes were

**Table 2.** Antimicrobial susceptibility of *Bacillus anthracis*. MIC: minimum inhibitory concentration. Representative data of three independent experiments are shown.

| Antimicrobial agent | MIC (µg/ml) |
|---------------------|-------------|
| Ampicillin          | 0.03        |
| Bacitracin          | 64          |
| Cefotaxime          | 16          |
| Chloramphenicol     | 4           |
| Ciprofloxacin       | 0.03        |
| Doxycycline         | 0.015       |
| Erythromycin        | 0.5         |
| Fosfomycin          | 128         |
| Gentamicin          | 0.06        |
| Kanamycin           | 0.5         |
| Lincomycin          | 0.25        |
| Meropenem           | 0.0005      |
| Rifampicin          | 0.03        |
| Spectinomycin       | 32          |
| Streptomycin        | 0.5         |
| Tetracycline        | 0.06        |
| Vancomycin          | 0.008       |

![Figure 3](image-url) **Figure 3.** Treatment of *B. anthracis* infection by antibiotics. a. Survival of silkworms (n = 10) with and without antibiotics treatment. Representative data from three independent experiments are shown. b, c. Survival of silkworms treated with various concentrations of doxycycline (b) or ampicillin (c) 16 h post-infection. Data are mean ± SEM of three independent experiments. ED$_{50}$ value was calculated by logistic regression analysis using the logit link function. d. Bacterial burden after 6 h and 9 h post-infection with and without antibiotics treatment (1 mg/kg). Statistical analysis was performed by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test compared with the wild-type. The dotted line shows the limit of detection.
colonized with bacteria (Figure 4(a)). While upon ampicillin treatment, only a few hemocytes were colonized with bacteria, and the overall presence of bacteria was decreased (Figure 4(b)). At 6 h post-infection, bacteria started proliferating outside the hemocytes (Figure 4(c)), while the ampicillin treated group had fewer bacteria engulfed in the hemocytes with no bacterial growth outside the hemocytes (Figure 4(d)).

Silkworm as a model to assess virulence of B. anthracis

With the establishment of the silkworm infection model of B. anthracis as shown above, we next used silkworms to evaluate the virulence of B. anthracis mutants. The toxin-related genes are known to have roles in B. anthracis virulence [47,48]. To test whether these toxins also act on silkworms, we used mutants with disruptions in pagA, lef, and atxA [49]. Located within a pathogenicity island on pXO1 [11], the pagA, lef, and atxA genes code for the protective antigen, the lethal factor, and a global virulence regulator AtxA, respectively. AtxA is reported to, directly and indirectly, regulate the transcription of several genes, including the pagA and lef genes [49,50]. We found that these mutants were less virulent in silkworms as they took a longer time to kill the larvae (Figure 5(a)) and had attenuated colonizing ability (Figure 5(b)). To demonstrate the use of silkworms in the quantitative determination of

![Figure 4](image_url)

**Figure 4.** Clearance of B. anthracis from silkworm hemolymph upon antibiotic treatment. Time course of B. anthracis clearance by antibiotic treatment at 3 h (a, b) and 6 h (c, d) post-infection are shown. Silkworms were infected with BYF10124 and injected with either vehicle (a, c) or 1 mg/kg ampicillin (b, d) at the specified time, hemolymph was obtained and visualized under the microscope. Scale bars, 20 µm.
virulence, we compared the \( LD_{50} \) values of wild-type and the mutants. We found that the \( LD_{50} \) values of the mutants were higher, suggesting reduced virulence (Figure 5(c)). Taken together, it was evident that the disruption of virulence-related genes decreases the virulence of \( B. \) anthracis to the silkworm and that the silkworm infection model can be used for quantitative evaluation of \( B. \) anthracis virulence.

\[ \text{Figure 5. Assessment of virulence of } B. \text{ anthracis mutants using silkworms. a. Survival of silkworms after infection with wild-type and virulence gene-disrupted mutants. Exponentially growing bacteria were injected into the hemolymph of silkworms, and survival was observed. Data are shown as a combined result from two independent experiments (n = 15). Injected CFU/larva: WT (wild-type) = 5 x 10^2 and 2.6 x 10^3; \Delta atxA = 4 x 10^2 and 3.4 x 10^3; \Delta lef = 7.5 x 10^2 and 2 x 10^3; \Delta pagA = 4.4 x 10^3 and 1.0 x 10^4. Statistical analysis was performed by Mantel-Cox log-rank test. b. Microbial burden of } B. \text{ anthracis wild-type and mutants in silkworms 6 h post-infection. Exponentially growing bacteria were injected into the hemolymph of silkworms, hemolymph was recovered 6 h post-infection, and CFU was determined. Data are shown as a combined result from two independent experiments (n = 27). Injected CFU/larva: WT (wild-type) = 2 x 10^2 and 3 x 10^3; \Delta atxA = 1.8 x 10^2 and 4.4 x 10^3; \Delta lef = 2.2 x 10^2 and 2.4 x 10^3; \Delta pagA = 1.1 x 10^3 and 2.8 x 10^3. Statistical analysis was performed by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test compared with the WT (* p < 0.05, **** p < 0.0001). The dotted line represents the limit of detection. c. Quantitative evaluation of virulence using silkworms. Exponentially growing bacteria were injected into the hemolymph of silkworms, and survival was observed. Data are mean \pm \text{SEM of three independent experiments for } \Delta atxA \text{ and } \Delta lef \text{ and six independent experiments for wildtype and } \Delta pagA. \text{ } LD_{50} \text{ value was calculated 16 h post-infection by logistic regression analysis using the logit link function. Statistical analysis was performed by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test compared with the WT (* p < 0.05, **** p < 0.0001).}

\]

Discussion

In this study, we established a silkworm model of \( B. \) anthracis infection and evaluated the therapeutic effects of clinically used antibiotics in silkworms infected with \( B. \) anthracis. Moreover, we generated a \( B. \) anthracis strain expressing AmCyan1, which was useful in evaluating the proliferation of bacteria inside
the host over time. While silkworm infection models of human pathogens have been reported [30,34,51–53], this is the first report of the silkworm infection model of *B. anthracis*. We found that *B. anthracis* Sterne killed silkworms and the LD$_{50}$ was 8.3 × 10$^2$ CFU, which was comparable with those in mice models where LD$_{50}$ ranged from 1.6 × 10$^2$–1.1 × 10$^3$ CFU [54,55]. Live bacteria were required for silkworm killing, which was evident from the fact that heat-killed bacteria (10$^6$ CFU) could not kill the larvae. *B. anthracis* established infection within silkworms as their proliferation was increased over time observed both from the increased CFU in the hemolymph of larvae and the increased proliferation of fluorescent bacteria under the microscope harvested at various intervals post-infection.

When we administered clinically used antibiotics to the *B. anthracis* infected silkworms in this study, we observed therapeutic activities of the antibiotics as they prolonged the survival of infected silkworms. Recovered CFU of bacteria from the treated silkworm hemolymph showed a faster clearance of bacteria in the ampicillin-treated group than in the doxycycline-treated group. As ampicillin is a bactericidal antibiotic, bacteria are killed in addition to clearance from the host immunity, which may have led to faster overall clearance; whereas, being a bacteriostatic antibiotic, doxycycline inhibited the bacteria growth, and overall clearance may have depended upon the host immunity taking a longer time. We further demonstrated, using fluorescent protein-expressing *B. anthracis*, that antibiotic treatment reduces bacterial burden in the hemolymph. The therapeutic effects of known antibiotics in the silkworm infection model imply that the therapeutic effectiveness of unknown compounds can be evaluated using this system, selecting for compounds with therapeutic activity and appropriate pharmacokinetics at an early stage of screening [37,38,40]. An additional advantage of using silkworms is that a small quantity of compounds would be enough to evaluate therapeutic effectiveness.

We found that *B. anthracis* kills the silkworms, and the lack of toxin genes makes *B. anthracis* less virulent to the worms when injected into the hemolymph. Among other invertebrates, *B. anthracis* can infect *G. mellonella* [25], but not *C. elegans* [56]. Furthermore, the ability of blood-feeding insects to act as vectors of *B. anthracis* [57] suggest a difference among invertebrate response toward *B. anthracis* when administered orally or into the hemolymph. Besides, invertebrates lack the anthrax toxin receptor [58] required for *B. anthracis* infection in mammals [59]. The detailed investigation of the mechanism of anthrax toxin-mediated toxicity in invertebrates would be a subject of future studies. Although silkworms do not have acquired immunity, innate immunity among silkworms is partly conserved with mammals, and several signaling cascades such as the mitogen-activated protein kinase (MAPK) pathways are activated in silkworms by bacterial components resulting in antimicrobial peptides production [60]. Thus, silkworms could differentiate the virulence of the mutant deficient in the lethal factor of *B. anthracis*, which acts via the MAPK pathway in mammals [61]. Among invertebrates, it has been shown that lethal factor cleaves *D. melanogaster* MAPK kinase [58]; however, its effect on silkworm MAPK kinases remains unknown.

Given that innate immunity is the first line of defense in all organisms [62], silkworms can be used to determine virulence factors that trigger the innate immunity and not the acquired immunity. Accordingly, evaluation of virulence factors of pathogenic microorganisms has been successfully performed using silkworm model [28,30,63–65]. The finding of this study showing attenuated virulence of strains of *B. anthracis* with disruption in known virulence genes suggested that silkworms can be used to evaluate the roles of unknown genes in the virulence of *B. anthracis*. Furthermore, since Sterne strain lacks pXO2 and is less virulent to higher animals [66], the silkworm model of *B. anthracis* Sterne infection will have an additional advantage for the identification of virulence factors encoded by genes either in the chromosome or pXO1 that might be masked in a highly virulent strain containing both pXO1 and pXO2.

**Acknowledgments**

We thank Dr. Takeshi Saito (International Institute for Zoonosis Control, Hokkaido University, Japan) for help with fluorescence microscopy and Tomoko Shimizu (International Institute for Zoonosis Control, Hokkaido University, Japan) for technical assistance. This manuscript has been released as a pre-print at bioRxiv (doi: 10.1101/2021.06.12.448172)

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by JSPS KAKENHI Grant Number 19K16653 and 21K15430 to AP, JP18K14672 to YF, and 18K19436 to HH and AMED Grant number JP21lm0125008 (the Japan Program for Infectious Diseases Research and Infrastructure) to AP, YF, and HH; Japan
Agency for Medical Research and Development
[JP21wm0125008]

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Atmika Paudel  http://orcid.org/0000-0003-3478-9452
Yoshikazu Furuta  http://orcid.org/0000-0003-4710-1389
Hideaki Higashi  http://orcid.org/0000-0002-5370-7865

References

[1] Fritz C. Taxonomy of the genus Bacillus and related genera: the aerobic endospore-forming bacteria. Phytopathology. 2004;94(11):1245–1248.
[2] Muturi M, Gachohi J, Mwatondo A, et al. Recurrent Anthrax Outbreaks in Humans, Livestock, and Wildlife in the Same Locality, Kenya, 2014-2017. Am J Trop Med Hyg. 2018;99(4):833–839.
[3] Yu D, He J, Zhang E, et al. Investigation and source-tracing of an anthrax outbreak in Gansu Province, China. PLoS One. 2018;13(8):e0203267.
[4] Leverin SS, Elvander M, Westermarck T, et al. Anthrax outbreak in a Swedish beef cattle herd–1st case in 27 years: case report. Acta Vet Scand. 2010;52(1):7.
[5] Hang’ombe MB, Mwansa JC, Muwowo S, et al. Human-animal anthrax outbreak in the Luangwa valley of Zambia in 2011. Trop Doct. 2012;42(3):136–139.
[6] Nayak P, Sodha SV, Bozalek EF, et al. A cutaneous Anthrax outbreak in Koraput District of Odisha-India 2015. BMC Public Health. 2019;19(53):470.
[7] Thapa NK, Tenzin, Wangdi K, et al. Investigation and control of anthrax outbreak at the human-animal interface, Bhutan, 2010. Emerg Infect Dis. 2014;20(9):1524–1526.
[8] Hanczakowski M, Reischl U, Holzmann T, et al. Injectional anthrax in heroin users, Europe, 2000-2012. Emerg Infect Dis. 2014;20(2):322–323.
[9] Navdarshavili A, Doker TJ, Geleishvili M, et al. Human anthrax outbreak associated with livestock exposure: Georgia, 2012. Epidemiol Infect. 2016;144(1):76–87.
[10] Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8(10):1019–1028.
[11] Okinaka RT, Cloud K, Hampton O, et al. Sequence and Organization of pXO1, the Large Bacillus anthracis Plasmid Haboring the Anthrax Toxin Genes. J Bacteriol. 1999;181(20):6509–6515.
[12] Makino S, Uchiyama T, Takada N, et al. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol. 1989;171(2):722–730.
[13] Gat O, Mendelson I, Chitlara T, et al. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol. 2005;58(2):533–551.
[14] McGillivray SM, Ebrahimi CM, Fisher N, et al. ClpX Contributes to Innate Defense Peptide Resistance and Virulence Phenotypes of Bacillus anthracis. J Innate Immun. 2009;1(5):494–506.
[15] Kern J, Schneewind O, BSA, the S-layer adhesin of B. anthracis, is a virulence factor for anthrax pathogenesis. Mol Microbiol. 2010;75(2):324–332.
[16] Chitlara T, Zaide G, Ehrlich S, et al. Htra is a major virulence determinant of Bacillus anthracis. Mol Microbiol. 2011;81(6):1542–1559.
[17] Jenkins A, Cote C, Twenhafel N, et al. Role of purine biosynthesis in Bacillus anthracis pathogenesis and virulence. Infect Immun. 2011;79(1):153–166.
[18] Israeli M, Elia U, Rotem S, et al. Distinct Contribution of the Htra Protease and PDZ Domains to Its Function in Stress Resilience and Virulence of Bacillus anthracis. Front Microbiol. 2019;10:255.
[19] Begun J, Sifri CD, Goldman S, et al. Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infect Immun. 2005;73(2):872–877.
[20] Diard M, Baerswisyl S, Clermont O, et al. Caenorhabditis elegans as a simple model to study phenotypic and genetic virulence determinants of extraintestinal pathogenic Escherichia coli. Microbes Infect. 2007;9(2):214–223.
[21] Tan MV, Rahme LG, Sternberg JA, et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A. 1999;96(5):2408–2413.
[22] Younes S, Al-Sulaiti A, Nasser EAA, et al. Drosophila as a Model Organism in Host-Pathogen Interaction Studies. Front Cell Infect Microbiol. 2020;10:214.
[23] Lee YJ, Jang HJ, Chung HY, et al. Drosophila melanogasteras a polymicrobial infection model for Pseudomonas aeruginosa and Staphylococcus aureus. J Microbiol. 2018;56:534–541.
[24] Needham AJ, Kibart M, Crossley H, et al. Drosophila melanogaster as a model host for Staphylococcus aureus-infection. Microbiology (Reading). 2004;150(7):2347–2355.
[25] Malmquist JA, Rogan MR, McGillivray SM. Galleria mellonella as an infection model for Bacillus anthracis Sterne. Front Cell Infect Microbiol. 2019;9:360.
[26] Cools F, Torfs E, Aizawa J, et al. Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae. Front Microbiol. 2019;10:311.
[27] Sheehan G, Dixon A, Kavanagh K. Utilization of Galleria mellonella larvae to characterize the development of Staphylococcus aureus infection. Microbiology (Reading). 2019;165(8):863–875.
[28] Paudel A, Hamamoto H, Panthee S, et al. Large-scale screening and identification of novel pathogenic Staphylococcus aureus genes using a silkworm infection model. J Infect Dis. 2020;221(11):1795–1804.
[29] Paudel A, Panthee S, Hamamoto H, et al. YbH regulates virulence genes expression and oxidative stress resistance in Staphylococcus aureus. Virulence. 2021;12(1):470–480.
[30] Kaito C, Kurokawa K, Matsumoto Y, et al. Silkworm pathogenic bacteria infection model for identification of novel virulence genes. Mol. Microbiol. 2005;56 (4):934–944.

[31] Fredericks LR, Lee MD, Roslund CR, et al. The design and implementation of restraint devices for the injection of pathogenic microorganisms into Galleria mellonella. PLoS One. 2020;15(7):e0230767.

[32] Dalton JP, Uy B, Swift S, et al. A Novel Restraint Device for Injection of Galleria mellonella Larvae that Minimizes the Risk of Accidental Operator Needle Stick Injury. Front Cell Infect Microbiol. 2017;7:99.

[33] Panthee S, Paudel A, Hamamoto H, et al. Advantages of the silkworm as an animal model for developing novel antimicrobial agents. Front Microbiol. 2017;8 (373). DOI:10.3389/fmicb.2017.00373

[34] Hamamoto H, Kurokawa K, Kaito C, et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob. Agents Chemother. 2004;48(3):777–779.

[35] Matsumoto Y, Ishii M, Hasegawa S, et al. Enterococcus faecalis YM0831 suppresses sucrose-induced hyperglycemia in a silkworm model and in humans. Commun Biol. 2019;2(1):157.

[36] Zhang X, Xue R, Cao G, et al. Silkworms can be used as an animal model to screen and evaluate gouty therapeutic drugs. J. Insect. Sci 2012;12.

[37] Hamamoto H, Urai M, Ishii K, et al. Lysoxin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat. Chem. Biol. 2015;11(2):127–133.

[38] Paudel A, Hamamoto H, Panthee S, et al. A novel spiro-heterocyclic compound identified by the silkworm infection model inhibits transcription in Staphylococcus aureus. Front Microbiol. 2017;8:712.

[39] Paudel A, Panthee S, Hamamoto H, et al. GPl0363 inhibits the interaction of RNA polymerase with DNA in Staphylococcus aureus. RSC Adv. 2019;9 (65):37889–37894.

[40] Paudel A, Panthee S, Urai M, et al. Pharmacokinetic parameters explain the therapeutic activity of antimicrobial agents in a silkworm infection model. Sci. Rep. 2018;8(1):1578.

[41] Plaut RD, Stibitz S. Improvements to a Markerless Allelic Exchange System for Bacillus anthracis. PLoS One. 2015;10(12):e0142758.

[42] Matsumoto Y, Yamazaki H, Yamasaki Y, et al. A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP. Sci Rep. 2020;10(1):10991.

[43] Matsumoto Y, Tatemaya Y, Sugita T. Evaluation of Antibacterial Drugs Using Silkworms Infected by Cutibacterium acnes. Insects. 2021;12(7):619.

[44] Frean J, Klugman KP, Arntzen L, et al. Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide. J Antimicrob Chemother. 2003;52(2):297–299.

[45] Furuta Y, Harima H, Ito E, et al. Loss of Bacitracin Resistance Due to a Large Genomic Deletion among Bacillus anthracis Strains. mSystems. 2018;3(5). DOI:10.1128/mSystems.00182-18

[46] Athamna A, Massalha M, Athamna M, et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother. 2004;53(2):247–251.

[47] Levy H, Weiss S, Alboum Z, et al. Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models. Infect Immun. 2012;80 (8):2623–2631.

[48] Levy H, Glinert I, Weiss S, et al. Toxin-independent virulence of Bacillus anthracis in rabbits. PLoS One. 2019;14(9):e028497.

[49] Furuta Y, Cheng C, Zorigt T, et al. Direct Regulons of AtxA, the Master Virulence Regulator of Bacillus anthracis. mSystems. 2021;e0029121. DOI:10.1128/mSystems.00291-21.

[50] Koehler TM. Bacillus anthracis genetics and virulence gene regulation. Curr Top Microbiol Immunol. 2002;271:143–164.

[51] Hosoda K, Koyama N, Hamamoto H, et al. Evaluation of Anti-Mycobacterial Compounds in a Silkworm Infection Model with Mycobacteroides abscessus. Molecules. 2020;25(21):4971.

[52] Matsumoto Y, Sekimizu K. Silkworm as an experimental animal for research on fungal infections. Microbiol Immunol. 2019;63(2):41–50.

[53] Yagi A, Yamazaki H, Terahara T, et al. Development of an invivo-mimic silkworm infection model with Mycobacterium avium complex. Drug Discov Ther. 2021;14(6):287–295.

[54] Wkllos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun. 1986;51(3):795–800.

[55] Chitlaru T, Israel M, Bar-Haim E, et al. Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain. Sci Rep. 2016;6(1). DOI:10.1038/srep18908

[56] Turner MJ, Cox JK, Spellman AC, et al. Avoidance behavior independent of innate-immune signaling seen in Caenorhabditis elegans challenged with Bacillus anthracis. Dev Comp Immunol. 2020;102:103453.

[57] Turell MJ, Knudson GB. Mechanical transmission of Bacillus anthracis by stable flies (Stomoxys calcitrans) and mosquitoes (Aedes aegypti and Aedes taeniorhynchus). Infect Immun. 1987;55(8):1859–1861.

[58] Guichard A, Park JM, Cruz-Moreno B, et al. Anthrax lethal factor and edema factor act on conserved targets in Drosophila. Proc Natl Acad Sci U S A. 2006;103 (9):3244–3249.

[59] Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol. 2003;19(1):45–70.

[60] Ishii K, Hamamoto H, Kamimura M, et al. Insect cytokine paralytic peptide (PP) induces cellular and humoral immune responses in the silkworm Bombyx mori. J Biol Chem. 2010;285(37):28635–28642.

[61] Tonello F, Montecucco C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol Aspects Med. 2009;30(6):431–438.

[62] Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2):S3–23.
[63] Hanaoka N, Takano Y, Shibuya K, et al. Identification of the Putative Protein Phosphatase Gene PTC1 as a Virulence-Related Gene Using a Silkworm Model of Candida albicans Infection. Eukaryot Cell. 2008;7 (10):1640–1648.

[64] Chieda Y, Iiyama K, Yasunaga-Aoki C, et al. Pathogenicity of gacA mutant of Pseudomonas aeruginosa PA01 in the silkworm, Bombyx mori. FEMS Microbiol Lett. 2005;244(1):181–186.

[65] Tran SL, Guillemet E, Ngo-Camus M, et al. Haemolysin II is a Bacillus cereus virulence factor that induces apoptosis of macrophages. Cell Microbiol. 2011;13(1):92–108.

[66] Sterne M. Avirulent anthrax vaccine. Onderstepoort J Vet Sci Anim Ind. 1946;21(41–43):